Updated Jul 10, 9:40 PM · 60 sources analyzed
Key Takeaways
Keros Therapeutics' TROPOS PAH study terminated mid-trial with no data disclosed — reason and pipeline impact remain unclear pending company statement.
Levomecor terminated both Phase 3 REL-1017 MDD trials simultaneously, effectively ending the program and removing a potential esketamine rival.
Today's sources are dominated by registry-level terminations and completions with no efficacy data; no market-moving clinical or regulatory events occurred.
📉 Loser
Levomecor — simultaneous termination of both Phase 3 MDD trials signals a program-level failure, ending REL-1017's path to approval
🔭 Watch Next
Watch for Keros Therapeutics to issue a public statement on the TROPOS termination rationale, which will determine whether this is a safety, futility, or strategic decision — likely within days given the registry update is now public.
Keros PAH Program Terminated: TROPOS Study Halted
Keros Therapeutics has terminated its Phase 2 TROPOS study (NCT05975905) of KER-012 in pulmonary arterial hypertension (PAH), a condition where the blood vessels supplying the lungs become dangerously narrowed. The termination of a randomized, placebo-controlled Phase 2 study — before completion — typically signals either a futility finding, safety concern, or strategic reprioritization, though no efficacy or safety data have been released from this registry update alone. The PAH space remains competitive, and the loss of another mechanism-of-mind candidate narrows the field of novel add-on therapies for patients already on background treatment.
ClinicalTrials.gov ↗Keros Therapeutics
KER-012 in Pulmonary Arterial Hypertension (PAH)
The TROPOS study (NCT05975905) was a randomized, double-blind, placebo-controlled Phase 2 study of KER-012 added to background PAH therapy. The registry has been marked Terminated. No efficacy or safety data have been released from this registry update — full data, if disclosed at all, are expected at a future medical meeting or publication.
Why it matters
A mid-study termination of a blinded, controlled Phase 2 without accompanying data disclosure is a yellow flag for the program's viability — the most benign explanation is strategic reprioritization, but futility or safety cannot be ruled out until the company speaks. Keros will need to clarify the reason publicly before the market can appropriately reprice the pipeline.
What to watch
Watch for a Keros Therapeutics press release or investor call explaining the TROPOS termination rationale — likely within days to weeks given the registry update is now public.
Levomecor
REL-1017 in Major Depressive Disorder (MDD)
Two separate Phase 3 studies of REL-1017 as adjunctive MDD treatment — NCT04855747 and NCT06011577 — are both now marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released via this registry update. The dual termination of both pivotal trials suggests the program is unlikely to proceed toward an NDA.
Why it matters
Terminating both Phase 3 trials simultaneously, rather than pausing one, makes a strategic pivot or partner-driven discontinuation the more likely explanation than a single-study anomaly — this looks like a program-level decision, not a trial-level one. The MDD adjunctive field is already crowded with approved options (esketamine, brexanolone analogs), and new entrants face a high bar for differentiation.
What to watch
Watch for any Levomecor public statement or SEC/regulatory disclosure explaining the termination rationale, which would clarify whether this was a safety, futility, or financing-driven decision.
United Therapeutics
Ralinepag in Pulmonary Arterial Hypertension (PAH)
The ADVANCE CAPACITY Phase 3 trial (NCT04084678) of ralinepag — assessing change in peak oxygen consumption by cardiopulmonary exercise testing (CPET) in WHO Group 1 PAH — is marked Terminated on ClinicalTrials.gov. No efficacy or safety results have been released via this registry update.
Why it matters
United Therapeutics already has a strong commercial PAH franchise, so the loss of ralinepag's CPET-focused Phase 3 is more a pipeline setback than an existential threat — but it does narrow the company's innovation story in a market where it faces growing competition from generics and biosimilars to treprostinil. The significance of the termination depends heavily on whether earlier ralinepag efficacy data were disappointing or whether this trial design itself was the issue.
What to watch
Watch for United Therapeutics' next earnings call or pipeline update for any commentary on ralinepag's development status and whether other ralinepag studies remain active.
Syndax Pharmaceuticals
Revumenib in Colorectal Cancer and Other Solid Tumors
Syndax's Phase 1/2 study (NCT05731947) of revumenib — an approved menin inhibitor — in colorectal cancer and other solid tumors has been marked Terminated. No efficacy or safety data from this solid tumor expansion have been released via the registry update.
Why it matters
The termination of a label-expansion exploration into solid tumors is a limited negative for Syndax — revumenib's approved hematology indication remains intact — but it does signal that the menin inhibitor mechanism may not translate cleanly outside of leukemia biology. Investors tracking Syndax for pipeline optionality should discount solid tumor upside from revumenib going forward.
What to watch
Watch for Syndax's pipeline day or next earnings call for commentary on whether any other solid tumor targets for revumenib remain under investigation.
The TROPOS study (NCT05975905) was a randomized, double-blind, placebo-controlled Phase 2 study of KER-012 added to background PAH therapy. The registry has been marked Terminated. No efficacy or safety data have been released from this registry update — full data, if disclosed at all, are expected at a future medical meeting or publication.
Why it matters
The termination removes KER-012 from the PAH pipeline, a space where novel add-on mechanisms are actively sought by prescribers and acquirers; investors will want to understand whether this was a safety, futility, or strategic decision.
Analysis
A mid-study termination of a blinded, controlled Phase 2 without accompanying data disclosure is a yellow flag for the program's viability — the most benign explanation is strategic reprioritization, but futility or safety cannot be ruled out until the company speaks. Keros will need to clarify the reason publicly before the market can appropriately reprice the pipeline.
What to watch
Watch for a Keros Therapeutics press release or investor call explaining the TROPOS termination rationale — likely within days to weeks given the registry update is now public.
Two separate Phase 3 studies of REL-1017 as adjunctive MDD treatment — NCT04855747 and NCT06011577 — are both now marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released via this registry update. The dual termination of both pivotal trials suggests the program is unlikely to proceed toward an NDA.
Why it matters
The loss of REL-1017 — a novel NMDA receptor channel blocker positioned as an alternative to esketamine — removes a potentially differentiated MDD option and signals continued attrition in the adjunctive depression space.
Analysis
Terminating both Phase 3 trials simultaneously, rather than pausing one, makes a strategic pivot or partner-driven discontinuation the more likely explanation than a single-study anomaly — this looks like a program-level decision, not a trial-level one. The MDD adjunctive field is already crowded with approved options (esketamine, brexanolone analogs), and new entrants face a high bar for differentiation.
What to watch
Watch for any Levomecor public statement or SEC/regulatory disclosure explaining the termination rationale, which would clarify whether this was a safety, futility, or financing-driven decision.
The ADVANCE CAPACITY Phase 3 trial (NCT04084678) of ralinepag — assessing change in peak oxygen consumption by cardiopulmonary exercise testing (CPET) in WHO Group 1 PAH — is marked Terminated on ClinicalTrials.gov. No efficacy or safety results have been released via this registry update.
Why it matters
Ralinepag was positioned as a next-generation prostacyclin receptor agonist (a class of drugs that relax blood vessels in the lungs) for United Therapeutics, and the termination of this exercise-capacity trial may reflect prior program setbacks or a strategic shift in the company's PAH portfolio.
Analysis
United Therapeutics already has a strong commercial PAH franchise, so the loss of ralinepag's CPET-focused Phase 3 is more a pipeline setback than an existential threat — but it does narrow the company's innovation story in a market where it faces growing competition from generics and biosimilars to treprostinil. The significance of the termination depends heavily on whether earlier ralinepag efficacy data were disappointing or whether this trial design itself was the issue.
What to watch
Watch for United Therapeutics' next earnings call or pipeline update for any commentary on ralinepag's development status and whether other ralinepag studies remain active.
Syndax's Phase 1/2 study (NCT05731947) of revumenib — an approved menin inhibitor — in colorectal cancer and other solid tumors has been marked Terminated. No efficacy or safety data from this solid tumor expansion have been released via the registry update.
Why it matters
Revumenib is already FDA-approved in relapsed/refractory acute leukemia, so the termination of its solid tumor expansion narrows the drug's label-growth story and removes a potential new revenue avenue.
Analysis
The termination of a label-expansion exploration into solid tumors is a limited negative for Syndax — revumenib's approved hematology indication remains intact — but it does signal that the menin inhibitor mechanism may not translate cleanly outside of leukemia biology. Investors tracking Syndax for pipeline optionality should discount solid tumor upside from revumenib going forward.
What to watch
Watch for Syndax's pipeline day or next earnings call for commentary on whether any other solid tumor targets for revumenib remain under investigation.
Sanofi's Phase 1/2 first-in-human study (NCT05086315) of SAR443579 — evaluated in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, high-risk myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm — is marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released via this registry update.
Why it matters
The termination of a broad first-in-human hematology program at Sanofi suggests an early signal failure or internal portfolio prioritization decision, removing an asset that was targeting several high-unmet-need blood cancers.
Analysis
For a company of Sanofi's scale, the termination of a single Phase 1/2 oncology asset is not a material financial event, but it does reflect continued attrition in the company's oncology pipeline — an area where Sanofi has been rebuilding through acquisitions. Investors focused on Sanofi's oncology pipeline depth should note the loss but keep it in context of a large diversified portfolio.
What to watch
Watch for Sanofi's next oncology pipeline review or R&D day for any acknowledgment of SAR443579's status and what, if any, replacement assets are entering the hematology clinic.
Etigilimab plus Nivolumab in Platinum-Resistant Clear Cell Ovarian Cancer
M.D. Anderson's Phase 2 EON study (NCT05715216) continues enrolling patients with platinum-resistant clear cell ovarian, fallopian tube, and primary peritoneal cancers to evaluate whether adding etigilimab — a TIGIT inhibitor (a checkpoint protein that can suppress immune responses against tumors) — to nivolumab improves disease control.
Why it matters
Clear cell ovarian cancer is notoriously platinum-resistant and has been largely unresponsive to PD-1 monotherapy; if dual checkpoint blockade targeting both PD-1 and TIGIT yields durable responses here, it could establish a new second-line standard in a subtype with very limited options.
Analysis
The EON study sits in a scientifically interesting but commercially uncertain space — TIGIT combination data from larger programs (notably Roche/Genentech's tiragolumab) have been mixed in other tumor types, so this trial is a crucial signal-finding effort for TIGIT's role in gynecologic oncology. BD teams watching for differentiated combination checkpoint assets in ovarian cancer should monitor EON's eventual data disclosure closely.
What to watch
Watch for M.D. Anderson to present EON efficacy data at a major gynecologic oncology conference — IGCS or SGO — likely in 2026 or 2027 depending on enrollment pace.
AstraZeneca's AZD2389 Phase 2 Completes in Liver Fibrosis
AstraZeneca's Phase 2 study (NCT06750276) of AZD2389 — evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with liver fibrosis and compensated cirrhosis — has been marked Completed on ClinicalTrials.gov, though no results have been released.
Why it matters
Liver fibrosis and cirrhosis remain areas of high unmet need with no approved antifibrotic agents; a completed Phase 2 safety/PK/PD dataset from AstraZeneca could inform whether AZD2389 has a viable path toward a larger efficacy trial in a space that has seen multiple late-stage failures.
Analysis
The completion of a safety and PK/PD Phase 2 is a necessary but not sufficient milestone — the question is whether AZD2389's mechanism shows enough pharmacodynamic activity (measurable biological effect in the target tissue) to justify Phase 3 investment in an indication where endpoint selection itself remains contested. AstraZeneca's decision on advancement will be the real tell.
What to watch
Watch for AstraZeneca to disclose AZD2389 Phase 2 results at EASL (European liver disease congress) or AASLD in late 2026, and for any subsequent Phase 3 initiation announcement.
Genmab Terminates GEN1042 Immunoradiotherapy Combination Study
Genmab's Phase 1/2 study (NCT05491317) evaluating GEN1042 — a bispecific antibody targeting CD40 and CD137 (immune-activating receptors that boost anti-tumor T cell responses) — in combination with radiotherapy, with or without pembrolizumab, in metastatic solid tumors has been marked Terminated.
Why it matters
The termination of a radiotherapy-immunotherapy combination study involving a bispecific T cell co-stimulator suggests early tolerability or activity signals were insufficient to warrant continued investment in this specific combination strategy, which could temper enthusiasm for similar immunoradiotherapy designs.
Analysis
GEN1042 is also under investigation in other combinations, so the termination of this arm is not necessarily the end of the asset — but it does narrow the therapeutic hypothesis for CD40/CD137 bispecifics in the radiation-sensitization context. Investors following Genmab's pipeline should track whether GEN1042 continues to advance in other study designs.
What to watch
Watch for Genmab's next pipeline update or R&D day for clarity on GEN1042's remaining active studies and any plans to advance the asset in combination regimens outside of radiotherapy.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.